40 results about "CDH1" patented technology

The invention discloses a mutant gene group for mammary cancer risk assessment and a detection kit thereof. The mutant gene group is a mutant gene set comprising the following seven genes: BRCA1 gene, BRCA2 gene, TP53 gene, MLH1 gene, MLH3 gene, MSH3 gene and CDH1 gene. The mutant gene group of the seven genes totally carries 25 mutant sites disclosed as Table 3. The invention also discloses a detection kit of the mutant gene group for mammary cancer risk assessment, which comprises probes or primers for detecting the mutant genes in the mutant gene group. The detection kit disclosed by the invention has the advantages of high detection efficiency, high detection speed, high detectable rate and the like.

The invention relates to a method and a kit for detecting cervical carcinoma by using PAX1 and CDH1 gene methylation. Particularly, the invention provides a kit, which contains (a) a primer pair aiming at methylation specificities and non-methylation specificities of a POX1 gene and a CDH1 gene, or contains (b) a methylation sensitivity restriction endonuclease, and a primer pair aiming at the specificities of the POX1 gene and the CDH1 gene. The kit can effectively separate the cervical carcinoma from cervicitis and HPV infection.

The invention provides a system for predicting prognosis of gastric cancer of subjects. The system comprises: a data acquisition module, which is used for acquiring clinical characteristic data of thesubjects, immune marker characteristic data of the subjects and protein expression data of the subjects; a data processing module, which is used for further processing the data acquired in the data acquisition module; and a module for calculating the prognosis risk of the gastric cancer of the subjects, wherein the module utilizes the data processed in the data processing module to calculate theprognosis risk values of the gastric cancer of the subjects, and groups the subjects based on the risk values. According to the system and a method provided by the invention, eight characteristics, including five immunomarkers (CD3, CD4, PDL1, PAX5, and GZMB), an EMT protein marker (CDH1) and two clinical characteristics (pTNM and age), are selected to develop the system and the method that can significantly improve prognostic ability of gastric cancer patients. The system and the method may be applicable to patients with or without neoadjuvant chemotherapy and exhibit predicted values, and the patients may benefit from post-operative adjuvant chemotherapy.

The invention relates to a CDH1 mutation detection kit and an application thereof. The kit mainly comprises the following main ingredients: (1) 19 pairs of CDH1 gene PCR amplifying and sequencing primers; and (2) PCR reagent for amplification. The PCR amplification product obtained by the kit can screen gene micromutation by a high-resolution dissolved curve process or carries out polymorphism analysis on restrictive segment length. The kit has high-efficiency mutation detection and functional evaluation actions. The invention is used for CDH1 gene mutation detection.

The present invention provides a method for predicting the treatment response of a human gastroesophageal cancer patient, the method comprising: a) measuring the gene expression of at least 3 of the following genes: CDH1, CDK6, COX2, ELOVL5, GATA4, EGFR, TBCEL, FGF7, CDH17, FNBP1, PIP5K1B, TWIST, CD44, MET, CEACAM1, TOX3, GLIPR2, GSTP1, RON, TMEM136, MYB, BRCA2, FGF1, POU5F1, EPR, DPYD, ABL2 and SH3RF1 in a sample obtained from the gastroesophageal tumour of the patient to obtain a sample gene expression profile of at least said genes; and b) making a prediction of the treatment response and/or prognosis of the patient based on the sample gene expression profile. Also provided are related computer-implemented methods and methods of treatment of gastroesophageal cancer.

The invention belongs to the field of research and development of genetic engineering antibody drugs, in particular, relates to a method for treating a tumor by administering Circ-CDH1. The Circ-CDH1 is a circular RNA Circ-CDH1 nucleic acid molecule or the protein Circ-CDH1-28 KD expressed by the circular RNA Circ-CDH1 nucleic acid molecule. In particular, a monoclonal antibody Anti-Circ-CDH1 is designed against Circ-CDH1-28 KD, which can specifically detect the content of a protein encoded by endogenous circular RNA Circ-CDH1, can remarkably inhibit invasion and metastasis of cells from tumors such as glioma, breast cancer and the like, and has wide application prospects in clinical detection of tumors and invasion and metastasis treatment.

The invention relates to a biomarker for breast cancer typing, and relates to the technical field of medical detection. When the biomarker is used for typing diagnosis of breast moistening ductal carcinoma or breast moistening lobular carcinoma, the biomarker comprises at least five genes such as CDH1, TP53, GATA3, CBFA2T3, MYC and the like, and the diagnostic power AUC can reach 0.8696; when the biomarker is used for breast cancer Luminal A type, breast cancer Luminal B type, breast cancer HER-2 overexpression type or basal sample breast cancer typing diagnosis, the biomarker comprises at least five genes such as TP53, ERBB2, PWWP2A, SPOP and RARA, the diagnostic power AUC can reach 0.8001, the biomarker has excellent diagnostic power, a molecular level-based discrimination method for different pathologies and molecular subtypes is provided, and the biomarker can be applied to diagnosis of breast cancer Luminal A type, breast cancer Luminal B type, breast cancer HER-2 overexpression type or basal sample breast cancer typing. And mutual verification is provided for pathological diagnosis results, so that case diagnosis results are ensured to be correct, and subsequent precise treatment is facilitated.

The invention discloses a mutant gene group, library and kit for evaluating female malignant tumor risk, and belongs to the technical field of biomedical molecular detection. The mutant gene group forevaluating the risk of female malignant tumors comprises one or more selected from a group consisting of the following 25 genes: ATM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53, BARD1, MRE11A, MUTYH, RAD50, XRCC2 and FANCC5. According to the invention, female malignant tumor related genetic markers can be widely screened andinspected, accuracy is higher, and a basis is provided for prediction, prevention and diagnosis of female malignant tumor onset risks.

Provided herein is a method of identifying the state of prostate cancer in a subject, and the method comprises the steps: 1) detecting the methylation level of a biomarker gene in a biological sample from the subject wherein the biomarker gene is selected from one or more of the following genes: APC, CCND2, CDH1, GSTP1, MCAM, PENK, PITX2, PTGS2, RARB, and RASSF1A; 2) comparing the methylation level detected in the step 1) with the normal methylation level of the corresponding biomarker gene in the population to determine the state of prostate cancer in the subject. Also provided herein are kits for identifying the state of prostate cancer in a subject. The method and the kit provided by the invention provide a rapid, reliable and accurate new way for prediction, diagnosis and evaluation of prostate cancer.

The invention belongs to the technical field of medical biology, and specifically discloses an autoantibody joint detection ELISA kit for early cardia adenocarcinoma screening. The kit comprises a solid phase carrier and a tumor-associated antigen coated on the solid phase carrier, and the tumor-associated antigen is composed of P53, CDH1, NRG1, MDM2, RHOA and IVL. Furthermore, the kit also comprises a sample diluent, a second antibody, a second antibody diluent, positive control serum, negative control serum, a developing solution, a stop solution and a washing solution. The ELISA kit provided by the invention can effectively detect cardia adenocarcinoma, especially early cardia adenocarcinoma, has detection sensitivity as high as 86% and specificity as high as 88%, can be used for large-scale screening of asymptomatic people in cardia adenocarcinoma high-incidence areas, and is beneficial to screening and early discovery of asymptomatic high-risk people.

The invention discloses a method for identifying the property of a thyroid nodule. The method comprises the step of detecting the DNA methylation levels of regions selected from the following (1) and (2) in a sample: (1) fragments of one or more genes selected from the following: RARG, PRR15, DPYS, MCC, TBX15, TSHR, DAPK and CDH1, and (2) nucleic acid regions within the upstream and downstream 10Kb of the genes described in (1).

The invention discloses a marker molecule related to endometrial cancer and application thereof in diagnosis of the endometrial cancer. Biomarkers include CDH1 and RPS4X, and the CDH1 and RPS4X are combined to have good diagnosis efficiency, high sensitivity and high specificity on the endometrial cancer. The invention further provides a product and a diagnosis system for diagnosing the endometrial cancer.

The present invention provides methods capable of predicting drug resistance of a tumor patient to immune checkpoint inhibitor therapy. The invention further provides drug-resistant genes AKT1 and/or CDH1, mRNA, cDNA or protein of the drug-resistant genes AKT1 and/or CDH1 and a detection reagent of the drug-resistant genes. The drug-resistant gene and the detection reagent thereof can be used for predicting the drug resistance of tumor patients to immunotherapy and the sensitivity of targeted therapy combined with or not combined with immunotherapy. The AKT1 and/or CDH1 gene mutation can be used as a biomarker for predicting the primary drug resistance of the immune checkpoint inhibitor therapy in dMMR/MSI-H gastrointestinal tumor patients, so that drug-resistant people can be accurately predicted, blind drug use is avoided, and the treatment economy of the immune checkpoint inhibitor therapy is improved.